No-moat Polynovo’s fiscal 2024 sales rose 54% to AUD 92 million, with 75% stemming from the main United States market. This increase largely reflects 197 new US customer accounts opened in the period to a total of 496, effective marketing featuring. The underlying group EBIT of AUD 1 million was close to our AUD 2 million forecast.
NovoSorb BTM is a sound alternative treatment option for dermal regeneration given it is synthetic, and its ease of use and clinical performance.
Polynovo is still burning cash and there is very high uncertainty on the success and timing of entering new geographies or potential new indications for NovoSorb.
|
Metric
|
PNV
|
NAN
|
FPH
|
|---|---|---|---|
Price/Earnings (Normalized) | 214.18 | 70.22 | 96.96 |
Price/Book Value | 24.98 | 6.14 | 11.54 |
Price/Sales | 17.74 | 6.64 | 11.60 |
Price/Cash Flow | 497.14 | 50.83 | 47.46 |
|
Metric
|
PNV
|
NAN
|
FPH
|
|---|---|---|---|
Quick Ratio | 2.87 | 5.25 | 0.88 |
Current Ratio | 3.41 | 6.16 | 1.83 |
Interest Coverage | 1.24 | 8.25 | 13.77 |
|
Metric
|
PNV
|
NAN
|
FPH
|
|---|---|---|---|
Return on Assets (Normalized) | 6.37% | 6.94% | 11.54% |
Return on Equity (Normalized) | 9.21% | 9.11% | 15.07% |
Return on Invested Capital (Normalized) | 6.83% | 7.18% | 13.94% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Hynsktyq | Glccpnd | $195.6 Bil | |||
| Stryker Corp
SYK
| Sqlrcvrcw | Zhyy | $137.3 Bil | |||
| Boston Scientific Corp
BSX
| Btqhrnzw | Lvfhz | $122.7 Bil | |||
| Medtronic PLC
MDT
| Mwskctvr | Nxrhjn | $114.6 Bil | |||
| Edwards Lifesciences Corp
EW
| Qdbhprchbq | Qkxcjjz | $40.1 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Tyfc | Ssxx | $30.7 Bil | |||
| DexCom Inc
DXCM
| Kfytllllpp | Kgqn | $27.0 Bil | |||
| Steris PLC
STE
| Jqcvfjcjj | Gfzwspd | $23.6 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Rmngmryfs | Hgdw | $22.0 Bil | |||
| Insulet Corp
PODD
| Qskltljgl | Rcfzb | $16.3 Bil |
United States